Zika Virus Vaccine Progresses Into Phase 1 Clinical Trial

This article originally appeared here.
Share this content:
Takeda’s Zika virus vaccine candidate is a purified, inactivated, alum-adjuvanted, whole Zika virus vaccine.
Takeda’s Zika virus vaccine candidate is a purified, inactivated, alum-adjuvanted, whole Zika virus vaccine.

An investigational Zika virus vaccine, TAK-426 (Takeda), has been granted Fast Track designation by the Food and Drug Administration (FDA).

TAK-426 is a purified, inactivated, alum-adjuvanted, whole vaccine candidate. It is currently being assessed in a Phase 1 clinical trial (ZIK-101) to evaluate safety and immunogenicity; a total of 240 individuals between the ages of 18 and 49 have been enrolled in the trial. 

There is currently no vaccine for Zika and the World Health Organization says the virus has spread to 84 countries, including the US. 

Reference

Takeda initiates phase 1 clinical trial of Zika vaccine candidate [press release]. New York, New York: Takeda America Holdings Inc. Published November 28, 2017. Accessed February 2, 2017.

You must be a registered member of Infectious Disease Advisor to post a comment.

Sign Up for Free e-newsletters